Carma Fund

Akribion Genomics develops gene-editing tools and cancer therapies using CRISPR nuclease technology.

Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

Symphera is a developer of an innovative surgical system focused on enhancing the efficiency of minimally invasive procedures. The company specializes in a laparoscopic surgical tool that aims to radically simplify and expedite surgical processes. By prioritizing control, autonomy, safety, and efficiency, Symphera enables healthcare providers to perform surgeries with greater precision and effectiveness. Through its all-in-one surgical system, the company is committed to transforming the landscape of surgical practices, making advanced medical techniques more accessible and streamlined for both practitioners and patients.

Thryve is a developer of a data and wearable application programming interface platform that facilitates access to fragmented health data from various medical devices and wearables. The company's software development kit (SDK) allows for seamless integration of health information from sources such as smartwatches and blood glucose meters, enabling users to harmonize their health data into a continuous stream of information. By supporting popular platforms like Apple Health, Google Fit, Huawei Health, and Samsung Health, Thryve empowers insurers, researchers, and developers to access real-time health sensor data. This integration enhances their ability to deliver personalized interventions and improve service offerings through the utilization of comprehensive health information.

Allogenetics GmbH specializes in innovative transplantation technology aimed at addressing organ rejection after transplantation procedures. The company has developed a first-in-class therapy that enhances graft survival by treating the transplant itself, rather than suppressing the patient's immune system. This approach significantly improves the quality of life for patients, allowing them to benefit from organ transplants without the need for lifelong immunosuppression. By focusing on the transplant rather than the immune response, Allogenetics offers a promising solution to a critical challenge in the field of organ transplantation.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

InContAlert is a deep tech startup focused on improving the lives of individuals with bladder dysfunction. The company has developed an mHealth device that monitors the filling level of the urinary bladder using deep learning algorithms. This technology provides real-time data to an associated app on smartphones or smartwatches, alerting users when their bladder reaches a predefined filling level. By doing so, InContAlert aims to reduce the need for unnecessary catheters and diapers, minimize the risk of uncontrolled urine loss, and help patients live more independently and comfortably.